Form 4: ECOR Director James Theofilos Granted RSUs

electroCore, Inc. Director James Charles Theofilos was granted 22,156 restricted stock units as part of the company's equity compensation plan.

Summary

• Director James Charles Theofilos of electroCore, Inc. (ECOR) received an equity grant on August 1, 2025.
• The grant consists of 22,156 restricted stock units (RSUs) at a price of $0 per unit, indicating a compensation grant.
• These RSUs were issued under the issuer's 2018 Omnibus Equity Compensation Plan.
• The RSUs are scheduled to vest in 12 equal quarterly increments over a 36-month period from the grant date.
• Following this transaction, Mr. Theofilos beneficially owns a total of 23,547 securities, which includes the 22,156 unvested RSUs and 1,391 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of aligned interests and a standard compensation practice, indicating commitment to long-term value creation, though it is a routine event.

Positives

• The grant of restricted stock units to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The equity compensation plan helps retain and motivate key personnel, contributing to stable leadership.

Negatives

• No direct negatives identified from this specific equity grant.

Risks

• NA

Future Outlook

The 22,156 restricted stock units are scheduled to vest in 12 equal quarterly increments over a 36-month period from the grant date of August 1, 2025, indicating a future increase in the director's vested common stock holdings.

Management Comments

• NA

Industry Context

The granting of restricted stock units to directors is a common practice in the biotechnology and medical device industry, used to align executive incentives with long-term shareholder value and retain key talent.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) with a multi-year vesting schedule is a standard compensation practice for directors in publicly traded companies, particularly within the healthcare and technology sectors, comparable to practices at companies like Medtronic or Boston Scientific for executive and board compensation.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Director James Charles Theofilos constitutes a related party transaction, executed under the company's established 2018 Omnibus Equity Compensation Plan.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value creation.
• Director: Provides a significant equity stake, incentivizing continued dedication and performance.

Next Steps

• The 22,156 restricted stock units will vest in 12 equal quarterly increments over the next 36 months, starting from August 1, 2025.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director as part of their compensation, which is a standard practice to align interests. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it reflects no significant new catalysts for a buy or sell decision based solely on this filing.

Keywords

electroCore, ECOR, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Compensation, James Charles Theofilos